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Angiotensin II regulation of vascular endothelial growth factor creases vascular permeability, and is chemotactic for
and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotox- monocytes [1]. VEGF also plays a role in wound healing,
icity. inflammation and tissue remodeling. Hypoxia and hypo-Background. Vascular endothelial growth factor (VEGF) is
glycemia are major stimulators of VEGF expression [2].involved in angiogenesis, wound healing and inflammation.
VEGF exerts its effect via the tyrosine kinase receptors Flt-1 Also, VEGF production is stimulated by a number of
and KDR/Flk-1. We have previously shown that VEGF is up- cytokines and growth factors including transforming
regulated in a chronic cyclosporine (CsA) nephrotoxicity growth factor- (TGF-), fibroblast growth factor, plate-model. Our current study examined the role of angiotensin II
let-derived growth factor (PDGF), keratinocyte growth(Ang II) blockade with enalapril (E) or losartan (L) on VEGF
in this model. factor, angiotensin II (Ang II), insulin-like growth fac-
Methods. Pair-fed salt-depleted rats were administered vehi- tor-1 (IGF-1) and reactive oxygen species (ROS) [3].
cle, CsA, CsA  nilvadipine, CsA  hydralazine/hydro- VEGF exerts much of its action by binding selectivelychlorthiazide (HCTZ), CsA  E or CsA  L, and were sacri-
and with high affinity to two tyrosine kinase receptorsficed at 7 or 28 days. Physiologic and histologic changes were
studied in addition to the mRNA expression of VEGF and its designated as Flt-1 (fms-like tyrosine kinase, also known
receptors Flt-1 and KDR/Flk-1 by Northern blot, and the pro- as VEGFR-1) and Flk-1 (fetal liver kinase-1, also known
tein expression of VEGF by Western blot. as KDR or VEGFR-2). Flt-1 binds VEGF with high af-Results. While all groups achieved similar blood pressures
finity but is poorly expressed, while KDR/Flk-1 bindsand creatinine clearances, the amelioration in nephrotoxicity
was observed only with Ang II blockade. VEGF mRNA and VEGF with somewhat lower affinity but is more readily
protein expressions increased with CsA and became signifi- detected [4]. VEGF receptors undergo dimerization and
cantly reduced with Ang II blockade. Flt-1 expression was
autophosphorylation after ligand binding, leading to acti-similar in all groups; it decreased early and remained low. On
vation of intracellular signal molecules such as mitogen-the other hand, KDR/Flk-1 mRNA expression was higher at
seven days in all groups, except in the E and L groups activated protein (MAP) kinase and phospholipase C.
where it was significantly lower, and then became further down- Until recently, most studies described VEGF receptors
regulated at 28 days.
expression as being specific to endothelial cells. How-Conclusions. The increased VEGF expression in chronic
ever, there are now several reports of non-endothelialCsA nephrotoxicity seems to be related to up-regulation of
Ang II. In addition, VEGF probably exerted its effect via cells expressing VEGF receptors [5].
the KDR/Flk-1 receptor. The actions of VEGF in this model The clinical use of cyclosporine (CsA) is limited by
remain speculative, but may be related to its effect on macro-
chronic nephrotoxicity, which is characterized by stripedphage infiltration or matrix deposition.
tubulointerstitial fibrosis and afferent arteriolar hyalino-
sis [6]. While acute nephrotoxicity results from intrarenal
vasoconstriction, the mechanism leading to chronic CsAVascular endothelial growth factor (VEGF) is an en-
nephrotoxicity remains unclear [7]. To study chronicdothelial cell mitogen that promotes angiogenesis, in-
CsA nephrotoxicity, a reproducible animal model was
developed with physiologic and histologic features thatKey words: chronic nephrotoxicity, enalapril, fibrosis, losartan, immu-
nosuppression, macrophages, matrix. resemble the human renal lesion described in patients
on long-term CsA therapy. Our previous studies haveReceived for publication June 27, 2001
shown that TGF-1 is involved in the fibrosis of thisand in revised form January 18, 2002
Accepted for publication March 4, 2002 model [8]. Apoptosis also plays a central role [9]. More
recently, we demonstrated an up-regulated expression 2002 by the International Society of Nephrology
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of VEGF mRNA and protein along with an increased (4) CsA  HH: Rats received a daily SC injection of
CsA 15 mg/kg plus hydralazine 10 mg/kg/day andexpression of Flt-1 and KDR/Flk-1 in this model [10].
In the kidney, VEGF is constitutively expressed pri- hydrochlorthiazide (HCTZ) 10 mg/kg/day (both
by matrix-driven delivery pellet).marily on glomerular visceral epithelial and tubular cells,
but its function is not fully delineated [3–5, 11]. Flt-1 (5) CsA  E: Rats received a daily SC injection of
CsA 15 mg/kg, and enalapril 10 mg/kg by gavage.and KDR/Flk-1 are present not only on renal endothelial
cells, but also on human mesangial and rat renal tubular (6) CsA  L: Rats received a daily SC injection of
CsA 15 mg/kg, and losartan 10 mg/kg by gavage.epithelial cells [3–5, 12]. VEGF plays a role in endothelial
development, in enhancing endothelial cell permeability
and in post-injury glomerular regeneration. Recently, an This dosage and route of administration for enalapril and
losartan were selected because they were respectivelyincreased VEGF expression was shown in renal biopsies
from recipients with chronic rejection [13]. Of note is previously shown to significantly block ACE activity and
AT1 receptors [17].that VEGF is increased in conditions associated with
macrophage infiltration, and that both chronic renal allo- On day 7 or 28, systolic blood pressure was measured
by tail plethysmography (Natsume Seisakusho Co. Ltd.,graft rejection and chronic CsA nephrotoxicity show a
heavy monocytic infiltration. Tokyo, Japan) and 24-hour urine samples were collected
in metabolic cages (Nalge Company, Rochester, NY,Angiotensin II plays an important role in pathological
extracellular matrix (ECM) accumulation in models of USA). The following day, the rats were anesthetized
with intraperitoneal ketamine, the abdomen was openedprogressive glomerulosclerosis and interstitial fibrosis,
independent of its effect on glomerular pressure [14]. On through a midline incision and the aorta was cannulated
retrogradely below the renal arteries with an 18-gaugethe other hand, angiotensin-converting enzyme (ACE)
inhibitors and angiotensin II subtype 1 (AT1) receptor needle. With the aorta occluded by ligation above the
renal arteries and the renal veins opened by a smallantagonists can reverse or attenuate fibrosis in a number
of animal and human kidney diseases [15]. In kidney incision for outflow, the kidneys were perfused with 20
mL of cold heparinized saline. The left kidney was re-transplantation, several lines of evidence suggest a role
for the renin-angiotensin system (RAS) in the develop- moved and processed for light microscopy and protein
analysis. After removing the right kidney, the cortex wasment and progression of chronic allograft injury [16].
We have previously shown that Ang II blockade resulted dissected from the medulla, and the cortex was processed
for RNA analysis. The animals were then euthanized byin the amelioration of CsA-induced fibrosis and in the
decrease in the expression of TGF-1 and matrix pro- deep anesthesia with ketamine followed by exsanguina-
tion.teins [17]. These data, together with the recent findings
that Ang II stimulates VEGF production [18], prompted
Drugsus to investigate whether Ang II regulates the production
of VEGF and the expression of receptors Flt-1 and KDR/ Cyclosporine A (Novartis Research Institute, East
Hanover, NJ, USA) was diluted in olive oil to a finalFlk-1 in a model of chronic CsA nephrotoxicity.
concentration of 15 mg/mL. VH consisted of an identical
volume of olive oil. Losartan (Du Pont Merck Pharma-
METHODS
ceutical, Wilmington, DE, USA) was dissolved in sterile
Experimental design water and orally given to animals at 10 mg/kg/day. Enala-
pril (Merck, Rahway, NJ, USA) was diluted in sterileThirty-two male Sprague-Dawley rats (Charles River,
Wilmington, MA, USA) weighing 225 to 250 g were water and orally given to animals at 10 mg/kg/day. Nil-
vadipine (Fujisawa, Osaka, Japan) was diluted in etha-used. They were housed in individual cages in a tempera-
ture and light controlled environment, received a low nol/olive oil and subcutaneously given to animals at 0.5
mg/kg/day. Matrix-driven delivery pellet of hydralazinesalt diet (0.05% sodium, Teklad Premier, WI, USA) and
were allowed free-access to water. After one week on and hydrochlorthiazide (Innovative Research of Amer-
ica, Toledo, OH, USA) were subcutaneously implantedlow salt diet, they were assigned to the following experi-
mental groups (N  5 to 6/group) and were sacrificed in animals and released at 10 mg/kg/day, respectively.
at 7 or 28 days.
Functional studies
Blood was collected from the jugular vein in plastic(1) Vehicle (VH): Rats received subcutaneous (SC)
injection of olive oil 1 mL/kg/day. syringes transferred to metal-free tubes and chilled on
ice. Plasma was harvested immediately by centrifugation(2) CsA: Rats received a daily SC injection of CsA
15 mg/kg. at 4C and stored at 70C until determined. Urinary
and plasma creatinine was measured by a Cobas Auto-(3) CsA  N: Rats received both a daily SC injection
of CsA 15 mg/kg and of nilvadipine 0.5 mg/kg. analyzer (Roche Diagnostics, Div. Hoffman-La Roche
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Inc., Nutley, NJ, USA). Creatinine clearance (CCr) was 18 hours with cDNA probes labeled with 32P-dCTP by
random oligonucleotide priming (Boehringer Mann-calculated using a standard formula. CsA blood level
was measured by a monoclonal radioimmunoassay for heim, Mannheim, Germany). Blots were washed in 2 
SSC, 0.1% SDS at room temperature for 15 minutes,CsA (Incstar Co., Stillwater, MN, USA).
and in 0.1  SSC, 0.1% SDS at 50C for 15 minutes.
Histology Films were exposed at 70C for different time periods
to ensure linearity of densitometric values and exposureTissue was fixed in 10% buffered formalin and embed-
ded in paraffin. Sections 2 to 4  thick were stained with time. Autoradiographs were scanned on an imaging den-
sitometer (GS-700; Bio-Rad Laboratories, Hercules,periodic acid-Schiff (PAS) reagent and trichrome stain
and examined by light microscopy. The histologic find- CA, USA). The density of bands for the glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRNA was usedings were subdivided into two categories: interstitial fi-
brosis and arteriolopathy. The findings of interstitial fibro- to control for differences in the total amount of RNA
loaded onto each gel line. Equal loading was furthersis consisted of matrix-rich expansion of the interstitium
with distortion and collapse of the tubules and thicken- ensured by the ethidium bromide gel inspection. For
quantitative purposes, values were divided by the den-ing of the tubular basement membranes. Features of in-
terstitial inflammation included mononuclear infiltrates, sity of bands for GAPDH in the same lane. The VEGF
cDNA probe used was a 384 bp Not I-EcoRI murineedema and vacuolization of interstitial cells. Arteriolopa-
thy consisted of hyalinization and destruction of afferent cDNA fragment of clone pT7T3D-Pac (American Type
Culture Collection, Rockville, MD, USA). The ratarterioles and terminal portions of interlobular arteries.
A minimum of 20 fields at 100 magnification were as- GAPDH cDNA probe (plasmid pBluescript KS II) was
a gift from J.M. Blanchard [19]. Flt-1 and KDR/Flk-1sessed and graded in each biopsy by an observer masked
to treatment groups using a color image analyzer (Nikon cDNA probes were derived from rat reverse transcrip-
tion-polymerase chain reaction (RT-PCR) products. ForE400, Nikon Inc., Tokyo, Japan; Pixera Professional digi-
tal camera, Los Gatos, CA, USA; Macintosh Powerbook Flt-1, both sense and antisense primers were located in
the extracellular region: sense 5-AGCCCACCTCTCG3, NIH Image v. 1.5). Interstitial fibrosis was estimated
by counting the percentage of injured areas per field of TATCCGCTGG, antisense 5-GGCGCTTCCGAATC
TCTA. For KDR/Flk-1, the primers were sense 5-AGCcortex and scored semiquantitatively using the following:
0  normal interstitium; 0.5  	5% of areas injured; TTGGCTCACAGGCAACATCGG (located in the sixth
IgG-like domain), antisense 5-TGGCCCCGCTTAAC1  5 to 15%; 1.5  16 to 25%; 2  26 to 35%; 2.5 
36 to 45%; and 3  
45%. Arteriolar hyalinosis was GGTCCGT (located between the transmembrane re-
gion and the intracellular domain). For RT-PCR, 5 gsemiquantitatively assessed by counting the percentage
of juxtaglomerular afferent arterioles available for exam- total RNA were combined with 2 L random primers
(Gibco BRL) and 2 L of Moloney murine leukemiaination with a minimum of 100 glomeruli per biopsy
assessed: 0  no arterioles injured; 0.5  	15%; 1  15 virus (MMLV) reverse transcriptase per the manufactur-
er’s instructions. RT product 1 to 2 L was amplifiedto 30%; 1.5  31 to 45%; 2  46 to 60%; 2.5  61 to
75%; and 3  
75%. using the Perkin-Elmer thermal cycler (Norwalk, CT,
USA). Cycles used for PCR for both Flt-1 and KDR/
Northern blot analysis Flk-1 were 94C for five minutes (once), 94C for one
minute, 58C for one minute, 72C for one minute (30Renal tissue was finely minced with a razor blade on
ice then homogenized in TRIzol reagent (Gibco Brl, cycles), and 72C for five minutes (once). PCR products
were electrophoresed in 1% agarose gel and photo-Grand Island, NY, USA). RNA extraction was per-
formed per the manufacturer’s protocol. After resuspen- graphed under ultraviolet light. The cDNA probes ob-
tained were sequenced and the correct sequences weresion in Tris-EDTA buffer, RNA concentrations were
determined using spectrophotometric readings at Ab- confirmed. The PCR products were cloned using the
Original TA Cloning kit (Invitrogen, Carlsbad, CA,sorbance260. RNA 30 g were electrophoresed in each
lane in 0.9% agarose gels containing 2.2 mol/L formalde- USA) per the manufacturer’s instructions.
hyde and 0.2 mol/L Mops (pH 7.0) and transferred to a
Western blot analysisnylon membrane (ICN Biomedicals, Costa Mesa, CA,
USA) overnight by capillary blotting. Nucleic acids were Frozen (70C) kidney tissue sections embedded in
Tissue-Tek O.C.T. (Miles Inc., Diagnostics Div., Elkhart,cross-linked by ultraviolet irradiation (Stratagene, La
Jolla, CA, USA). The membranes were prehybridized IN, USA) were processed for protein extraction as pre-
viously described. Equal amounts of protein were re-for two hours at 42C with 50% formamide, 10% Den-
hardt’s solution, 0.1% sodium dodecyl sulfide (SDS), 5 solved on 15% SDS-PAGE gel (Bio-Rad) and then elec-
troblotted to nitrocellulose membranes (Bio-Rad). Afterstandard saline citrate (SSC), and 200 g/mL denatured
salmon sperm DNA. They were hybridized at 42C for blocking the membranes for one hour with TBS-T, they
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Table 1. Physiologic changes in the experimental groupswere incubated with goat polyclonal VEGF antibody
(1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, Blood CsA blood Serum Creatinine
pressure level creatinine clearanceCA, USA). The secondary antibody was anti-goat
mm Hg ng/mL mg/dL mL/min/100 g(1:2000 dilution; Santa Cruz Biotechnology) conjugated
7 dayswith alkaline phosphatase. The detection of signal em-
VH 1522 00 0.590.04 0.360.01ployed a colorimetric subtraction kit (Zymed, San Fran- CsA 1498 2752136 0.630.02 0.300.01
cisco, CA, USA). CsA  N 1222a 2693204 0.650.07 0.270.05
CsA  HH 1066a 2425282 0.720.06 0.320.03
CsA  E 1086a 2819351 1.110.20a 0.190.04aImmunohistochemical staining
CsA  L 984a 3391326 1.450.16a 0.150.02a
Four-micron sections of formalin-fixed, paraffin-embed- 28 days
VH 1432 00 0.570.02a 0.390.02aded tissue were cleared with xylene and hydrated using
CsA 1444 5164270 1.020.06 0.200.01decreasing concentrations of ethanol. For VEGF immu-
CsA  N 1255a 5256309 1.060.07 0.220.02
nostaining, the primary antibody used was a rabbit poly- CsA  HH 986a 4295293 1.140.06 0.180.01
CsA  E 904a 4488658 1.850.16a 0.110.01aclonal antibody to human VEGF (Santa Cruz Biotech-
CsA  L 934a 4374688 2.370.41a 0.090.01anology). To identify macrophages, a mouse monoclonal
Data are mean  SEM of 5-6 animals. Abbreviations are: VH, placebo; CsA,IgG1 antibody to rat macrophages (ED1; Serotec, Ox-
cyclosporine; N, nilvadipine; HH, hydralazine-hydrochlorthiazide; E, enalapril;ford, UK) was used. Staining for VEGF and ED1 was L, losartan.
a P 	 0.05 vs. CsA onlyperformed in three representative animals from the VH-,
CsA-, and CsA  L-treated rats sacrificed at 28 days.
Control experiments included omission of either the pri-
mary or secondary antibody. are summarized in Table 1. There were no significant
All sections for VEGF staining were subjected to anti- differences in body weight or in the rate of weight gain
gen retrieval using immersion in a 0.1 mol/L citrate buffer suggesting that food intake was comparable in all groups
(pH 6.0), followed by heating in an electrical pressure (data not shown). CsA blood levels increased progres-
cooker for three minutes (total time 30 min). All steps sively and, at the end of each treatment period, similar
were carried out at room temperature. The primary levels were achieved. CsA-induced hypertension was not
VEGF antibody was applied overnight at a dilution of observed in this model. Despite that, addition of losartan
1:100. This was followed sequentially by incubation for or enalapril caused an early sustained and significant
30 minutes with a secondary anti-rabbit IgG antibody decrease in blood pressure (P 	 0.05 at 7 and 28 days
(Sigma, St. Louis, MO, USA) at a dilution of 1:300 and
vs. CsA-only group). In order to control for the effectstreptavidin peroxidase-conjugated (Dako, Carpenteria,
of blood pressure on interstitial fibrosis, rats were ran-CA, USA), with color development using diaminobenzi-
domized to receive CsA  N or CsA  HH for 7 or 28dine (DAB; Dako) for five minutes.
days with blood pressure reductions similar to theImmunostaining for macrophages was carried out us-
CsA  E and CsA  L groups being achieved. All CsA-ing a slide autostainer (Ventana, Tucson, AZ, USA).
treated animals had a significant increase in their serumAll steps were performed at 37C. Slides were pretreated
creatinine by day 28 (P	 0.05 vs. VH group) and experi-by Protease 2 enzyme digestion for 12 minutes. The
enced a decline in their glomerular filtration rates asprimary antibody (ED1) was applied at a dilution of
estimated by creatinine clearance (CCr). This was present1:800 for 32 minutes. This was followed by incubation
by day 7 but became more significant at 28 days (P 	for 8 minutes with a secondary anti-mouse IgG antibody
0.05 vs. VH group). Animals treated with CsA  N or(Vector Labs, Burlingame, CA, USA) at a dilution of
CsA  HH had a significantly higher GFR compared1:300. Detection steps were then performed using the
to those treated with CsA  E or CsA  L (P 	 0.05).basic DAB kit from Ventana.
There were no significant differences in CCr between the
Statistical analysis CsA only, CsA  N and CsA  HH groups.
Results are presented as mean standard error. Com-
Histologic changesparisons between groups were done by analysis of vari-
The histologic changes observed are summarized inance (ANOVA; the Kruskal-Wallis test followed by Tu-
Table 2. VH-treated rats demonstrated a normal kidneykey test). The level of statistical significance was chosen
histology (Fig. 1A, B). By contrast, the kidneys of CsA-as P 	 0.05.
treated rats developed a striped pattern of tubulointersti-
tial fibrosis and tubular atrophy (Fig. 1C) in addition to
RESULTS afferent arteriolar hyalinosis (Fig. 1D). When the extent
Physiologic studies of the histological changes was graded using a 0 to 3
semiquantitative score, most of the differences were ob-Values for serum creatinine, creatinine clearance, sys-
tolic blood pressure, and CsA whole blood trough levels served at 28 days (Table 2). The concurrent administra-
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Table 2. Histologic semiquantitative scoring 0.05 vs. CsA only group) by approximately 35 to 40%
at 7 days and by 27 to 28% at 28 days. Of note is thatTubulointerstitial fibrosis Arteriolopathy
the effect of Ang II blockade was observed more signifi-7 days 28 days 7 days 28 days
cantly early, at 7 days, when compared to 28 days. While
VH 00 00a 0.10.1 0.20.1a
nilvadipine decreased the mRNA and protein expres-CsA 00 1.50.3 0.10.1 1.80.2
CsA  N 00 1.30.3 0.10.1 1.70.2 sions of VEGF at both 7 and 28 days, the difference did
CsA  HH 0.10.1 2.10.2 0.10.1 2.10.1 not achieve statistical significance. On the other hand,
CsA  E 00 0.80.2a 0.10.1 0.30.1a
treatment with hydralazine/HCTZ resulted in no changeCsA  L 00 0.70.1a 0.10.1 0.30.1a
in VEGF mRNA or protein expression.Data are meanSEM of 5–6 animals. Abbreviations are VH, placebo; CsA,
cyclosporine; N, nilvadipine; HH, hydralazine-hydrochlorthiazide; E, enalapril; The immunohistochemical staining for VEGF at 28
L, losartan. days is shown in Figure 5 and was mostly present in theaP 	 0.05 vs. CsA only
corticomedullary junction and in the outer medullary
areas. CsA-treated rats exhibited a strong, diffuse and
granular cytoplasmic staining for VEGF. This was mostly
seen in the tubulointerstitium with strongly positivetion of losartan or enalapril with CsA dramatically and
(more than 90%) staining in both proximal and distalequally improved the tubulointerstitial fibrosis (P 	
tubular epithelial cells. There was also positive staining0.05) and the afferent arteriolopathy (P 	 0.01) when
of occasional glomerular podocytes. This was in sharpcompared to the CsA-only treated group (Fig. 1 E, F).
contrast with VH-treated rats that showed only focal,On the other hand, CsA-induced tubulointerstitial fi-
faint and non-specific cytoplasmic staining for VEGF inbrosis was not affected by the concurrent use of nilvadi-
tubular epithelial cells. On the other hand, treatment ofpine and worsened with the hydralazine-HCTZ combi-
CsA rats with losartan reduced greatly the intensity ofnation (Table 2). Of note is that the beneficial effect of
VEGF staining in tubular epithelial cells. In addition,Ang II blockade was more significant in preventing CsA-
VEGF-positive cells colocalized in serial sections withinduced arteriolopathy than in ameliorating the tubulo-
the ED1 marker for macrophages.interstitial fibrosis.
There was also a difference in the number of ED1-
Expression of Flt-1 and KDR/Flk-1 receptorspositive macrophages at 28 days (Fig. 2). In the VH-
The mRNA expressions of the Flt-1 and KDR/Flk-1treated rats, there were very few macrophages in the
receptors were similar in the VH-treated groups andinterstitium. However, CsA-treated kidneys displayed
were lower than the levels observed in CsA only-treatedlarge numbers of macrophages infiltrating the tubuloin-
kidneys (Figs. 6–8). CsA treatment increased the mRNAterstitium. On the other hand, those animals treated with
expression of Flt-1 and KDR/Flk-1 early at seven daysCsA and losartan showed only rare macrophages. The
(P 	 0.01 vs. VH group); CsA increased KDR/Flk-1number of macrophages identified in the glomeruli was
expression to a greater extent than Flt-1. Flt-1 receptornot different between the three groups.
became significantly down-regulated early (P 	 0.05 vs.
VH) in all the treated groups and its expression seemedVEGF expression
to be independent of the antihypertensive agent usedThe mRNA expression of VEGF was clearly up-regu-
(Figs. 6 and 8). Its expression remained low and un-lated in the CsA-treated rats as compared to the VH-
changed at 28 days and no specific effect was observedtreated rats (Figs. 3 and 8). This effect was seen early
with Ang II blockade. On the other hand, the behavior ofat 7 days (P 	 0.05), and it progressively increased and
the KDR/Flk-1 mRNA receptor was somewhat differentcontinued to be significant in the CsA-treated kidneys
(Figs. 7 and 8). It declined with time and was higher atat 28 days (P 	 0.05). Ang II blockade with losartan or
7 days compared to 28 days possibly due to VEGF down-enalapril equally decreased VEGF mRNA expression
regulating its own receptor. There was a specific effect(P 	 0.05) by approximately 40 to 50% at 7 days and
observed with Ang II blockade where both enalaprilby 22 to 24% at 28 days compared to the CsA only
and losartan significantly decreased KDR/Flk-1 mRNAgroup. To assess whether the changes in the mRNA
expression at both time points studied (P 	 0.05 vs. VH
expression were translated into changes in the synthesis
group). However, a similar effect was not observed in
of VEGF peptide, Western blots were performed on the CsA  N and CsA  HH groups where there was
tissue homogenates derived from the whole cortex. The a trend toward a lower KDR/Flk-1 expression, but the
protein expression of VEGF was similar to its mRNA difference did not achieve statistical significance.
(Figs. 4 and 8) in that it increased at day 7 (P 	 0.05)
and more so at day 28 (P 	 0.05) in CsA-treated rat
DISCUSSIONkidneys when compared to VH-treated rats. Similarly,
Ang II blockade with losartan or enalapril equally and We have previously shown that the expression of
VEGF and its receptors Flt-1 and KDR/Flk-1 was up-significantly decreased VEGF peptide production (P 	
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Fig. 1. Histologic changes. Photomicrographs showing the renal cortex of a salt-depleted rat given vehicle (VH; A, B), cyclosporine A (CsA) 15
mg/kg/day (C, D), or a combination of CsA 15 mg/kg/day and losartan 10 mg/kg/day (E, F ). VH-treated rats display normal kidney histology
(A, B). In rats treated with CsA, extensive interstitial fibrosis and tubular atrophy (C) and afferent arteriolopathy (D) are seen. When both CsA
and losartan are given in combination, these changes are markedly reduced (E, F). Trichrome (A, C, E), PAS (B, D, F). Original magnification
200.
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Fig. 2. Infiltration by macrophages in chronic CsA nephrotoxicity. Kid- Fig. 5. Immunohistochemical staining for VEGF: Kidney sections from
VH-treated (A), CsA-treated (B) and CsAL-treated (C ) rats for 28ney sections from VH-treated (A), CsA-treated (B) and CsA L-treated
(C ) rats for 28 days were stained with ED1, an antibody to macrophages. days were stained with an antibody to VEGF. (B) CsA-treated rats
exhibited a strong and diffuse tubular epithelial staining. (A) In contrast,While VH-treated rats had very few macrophages (A), CsA-treated
kidneys displayed large numbers of macrophages infiltrating the tubu- the staining for VH-treated rats was faint and non-specific. (C) Treat-
ment with losartan of CsA rats greatly reduces the intensity of VEGFlointerstitium (B). On the other hand, those animals treated with CsA
and losartan showed only rare macrophages (C). Original magnification staining. Original magnification 400.
400.
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Fig. 4. Vascular endothelial growth factor (VEGF) protein expression
by Western blot. Protein was isolated from whole cortex at 7 and 28Fig. 3. Northern blot expression of vascular endothelial growth factor
days and hybridized with a goat polyclonal anti-mouse VEGF antibody.(VEGF) mRNA. Total RNA was isolated from whole cortex at 7 and
Results of the densitometric analysis of equal amounts of protein are28 days and hybridized with a cDNA probe to VEGF. (A) Results of
shown (A). *P 	 0.05 vs. CsA only group. Symbols are: ( ) CsA  L;densitometric analysis after correcting for GAPDH mRNA. Symbols
( ) CsA  E; ( ) CsA  HH; ( ) CsA  N; () CsA; () VH.are: () placebo (VH); () cyclosporine (CsA); ( ) CsA nilvadipine
Abbreviations are in Fig. 3. (B) Representative Western blot. N  5(N); ( ) CsA  hydralazine-hydrochlorthiazide (HH); ( ) CsA 
to 6 per group.enalapril (E); ( ) CsA  losartan (L). *P 	 0.05 vs. CsA only group.
(B) A representative Northern blot. N  5 to 6 per group.
the use of nilvadipine or with hydralazine/HCTZ failed
to achieve similar results. In addition, the effects of ena-regulated in chronic CsA nephrotoxicity [10]. These
changes were seen only in rats on low salt diet in which lapril and losartan on kidney histology and VEGF ex-
pression were comparable.nephrotoxicity developed and not in rats on normal salt
diet that remained disease free. This led to the suggestion Previous reports have demonstrated that Ang II is a
potent stimulus for VEGF in vascular smooth muscle,that CsA nephrotoxicity, and not merely CsA adminis-
tration, is responsible for the enhanced VEGF expres- cardiac and retinal endothelial, and mesangial cells
[21–26]. This action is Ang II concentration-dependentsion. Since a low salt diet activates the RAS, we exam-
ined the effect of Ang II blockade on VEGF expression. and is rapid in onset [26]. Ang II exerts its multiple
actions via specific receptors. To date, most of the recog-Our prior study showed that Ang II blockade amelio-
rated chronic CsA nephrotoxicity [17]. Our current study nized biological actions of Ang II are transduced via the
AT1 receptor [27]. In this model, the RAS is clearlyshows a similar beneficial effect, namely a reduction in
interstitial fibrosis and arteriolopathy. The protective ef- activated and the effects exerted by CsA on VEGF were
abolished by losartan, suggesting the involvement of thefect of RAS blockade on the kidney was dissociated from
its renal hemodynamic effects, since there was worsening AT1 receptor. This is similar to other studies that showed
that AT1 receptor antagonists, but not AT2 antagonists,of the GFR in the losartan and enalapril-treated rats, a
finding similar to previous observations in the same model are capable of inhibiting completely the effect of Ang II
on VEGF [28]. Our results do not necessarily contradict[17, 20]. Part of the beneficial effects of Ang II blockade
also could have been related to its antihypertensive effect. recent findings that VEGF infusion improved CsA-asso-
ciated hypertension in rats on a high-salt diet since, un-However, more interestingly, VEGF mRNA expression
and peptide production were specifically and significantly like our model, the RAS in this setting was blunted
[29]. Also, we did not investigate the mechanism throughreduced by Ang II blockade. This effect was seen early,
persisted at 28 days, and was independent of blood pres- which Ang II affected VEGF expression. It could be due
to an inhibition in mRNA transcription and/or a decreasesure since a comparable decrease in blood pressure with
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Fig. 6. Northern blot expression of Flt-1 mRNA. Total RNA was iso-
lated from whole cortex at 7 and 28 days and hybridized with a cDNA
Fig. 7. Northern blot expression of KDR/Flk-1 mRNA. Total RNAprobe to Flt-1. (A) Results of densitometric analysis after correcting
was isolated from the whole cortex at 7 and 28 days and was hybridizedfor GAPDH mRNA. Symbols are: () VH; () CsA; ( ) CsA  N;
with a cDNA probe to KDR/Flk-1. (A) Results of densitometric analysis( ) CsA  HH; ( ) CsA  E; ( ) CsA  L. Abbreviations are in
after correcting for GAPDH mRNA. Symbols are: () VH; () CsA;Figure 3 legend. (B) Representative Northern blot. N  5-6 per group.
( ) CsAN; ( ) CsAHH; ( ) CsA E; ( ) CsA L. Abbrevia-*P 	 0.05 vs. CsA only group.
tions are in Figure 3 legend. (B) Representative Northern blot. N  5
to 6 per group. *P 	 0.05 vs. CsA only group.
in mRNA stability. In hypoxia, VEGF was increased in
human epithelial cells through increasing mRNA tran- VEGF receptors expression. KDR/Flk-1 decreased in a
scription and stability [30]. On the other hand, Ang II
manner similar to VEGF, an effect not seen in the other
was able to activate VEGF transcription in bovine retinal
groups. On the other hand, the behavior of Flt-1 was
pericytes without changing the mRNA half-life [25]. It
independent of Ang II. Based on these findings, we con-is interesting to note that the VEGF gene contains a
clude that VEGF probably exerted its biological effectnumber of motifs in the 3 untranslated region involved
in this model via KDR/Flk-1. It also is possible thatin regulating mRNA stability [31].
Ang II may directly regulate KDR/Flk-1 gene expres-There is convincing evidence in vitro and in vivo that
sion. Recently, in a report investigating Ang II activityAng II increases TGF- [32] and that Ang II blockade
in retinal endothelial cells, Ang II potentiated VEGF-decreases TGF- [14]. Along those lines, we have shown
induced angiogenic activity through KDR/Flk-1 but hadthat Ang II blockade decreases TGF-1 in chronic CsA
no effect on Flt-1 [21]. These two receptors display differ-nephrotoxicity [17]. Since TGF- induces VEGF in sev-
ences in function; for example, KDR/Flk-1-expressingeral cell types [1, 3, 26], it is conceivable that Ang II-
cells show changes in morphology, chemotaxis, and mito-induced VEGF could be mediated via Ang II-induced
genicity upon VEGF stimulation, whereas Flt-1-express-release of TGF-. However, two lines of evidence negate
ing cells lack such response [1, 32]. Also, gene knockoutthis possibility: (1) Ang II actions to increase VEGF
experiments suggest differences in vascular developmentoccur rapidly and earlier than the time course for TGF-
[1]. It is thought that Flt-1 is not a signal receptor, butinduction by Ang II [18]; (2) the released TGF-1 is in
rather a “decoy” receptor that negatively regulatesthe latent form by bioassays [22]. These observations do
VEGF by sequestering it and rendering it less availablenot necessarily exclude the possibility that more pro-
to KDR/Flk-1 [33]. However, subsequent studies indi-longed Ang II stimulation, by allowing time for TGF-
cated that Flt-1 interacts with some signal transducingproduction, could increase VEGF directly via the AT1
proteins [32, 34]. Nevertheless, most studies support thereceptor and indirectly via TGF-.
We also investigated the effect of Ang II blockade on hypothesis that interaction with KDR/Flk-1 is a critical
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Fig. 8. Time course for the expression of
VEGF and its receptors Flt-1 and KDR/Flk-1.
Symbols are: () placebo; () CsA; ()
CsA  N; () CsA  HH; () CsA  E;
() CsA  L. Abbreviations are in Figure 3
legend. N  5 to 6 per group.
requirement to induce the full spectrum of VEGF biolog- know that VEGF is chemotactic for macrophages and
is increased in conditions associated with macrophageical responses. In support of this, VEGF mutants that
bind selectively to KDR/Flk-1 are fully active endothelial infiltration. In human chronic rejection, VEGF-positive
cells in the interstitium colocalized with macrophagescell mitogens and anti-idiotypic antibodies that activate
KDR/Flk-1 promote tumor angiogenesis [35, 36]. In ad- [13]. It is also important to note that our CsA model
displays a mononuclear infiltrate that precedes intersti-dition, it used to be believed that VEGF receptors were
restricted to the endothelium and that VEGF exerts its tial fibrosis and that is improved by Ang II blockade
[17]. In this experiment, the number of mononuclearactivity in an autocrine fashion. However, recent findings
confirmed the presence of VEGF receptors on nonendo- cells increased with CsA administration and later de-
clined with losartan treatment. Moreover, VEGF expres-thelial cells and suggested that VEGF acts also in a para-
crine fashion [37]. sion colocalized with that of ED-1 positive cells in serial
sections. This suggests that either VEGF is produced byWhat effect VEGF actually has on chronic CsA neph-
rotoxicity remains unclear because the renal actions of macrophages or that it is contributing to their recruit-
ment into the interstitium. Moreover, Ang II is knownVEGF remain speculative. A study in patients with
chronic renal disease noted an up-regulated VEGF ex- to play a role in the progression of glomerular and tubu-
lointerstitial fibrosis [41]. Thus, it is possible that Ang IIpression in the interstitium, but the signals were reduced
in globally sclerosed glomeruli [38]. These results are blockade, by decreasing VEGF, is capable of decreasing
monocytic attraction, thereby aborting a self-perpetuat-consistent with a temporal sequence in which VEGF
expression precedes renal fibrosis and is then down-regu- ing loop of myofibroblast proliferation and interstitial
fibrosis.lated or disrupted after fibrosis. Further studies are
needed to determine whether VEGF is in fact a signaling The results reported herein raise some intriguing ques-
tions. Since VEGF is a potent endothelial cell mitogen,molecule involved in enhancing glomerular sclerosis or
interstitial fibrosis. More recently, VEGF was shown to it is possible that Ang II-induced VEGF production is
a compensatory mechanism directed at replacing theactivate MAP kinase and to enhance collagen synthesis
in human mesangial cells [39]. Of interest, VEGF also damaged endothelium caused by CsA. In addition, it is
possible that VEGF plays a role, either independentlywas reported to induce interstitial collagenase in endo-
thelial cells but not in fibroblasts [40]. Thus, both matrix or through Ang II, in CsA-induced fibrosis. This may
be related either directly through its effect on matrixsynthesis and degradation may be regulated by VEGF
through contrasting actions on renal cells. Moreover, we remodeling or indirectly through its chemotactic effect
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